53.33
price up icon1.27%   0.67
after-market Handel nachbörslich: 53.33
loading
Schlusskurs vom Vortag:
$52.66
Offen:
$52.53
24-Stunden-Volumen:
526.90K
Relative Volume:
0.46
Marktkapitalisierung:
$4.10B
Einnahmen:
$35.93M
Nettoeinkommen (Verlust:
$-244.56M
KGV:
-13.50
EPS:
-3.95
Netto-Cashflow:
$-157.31M
1W Leistung:
-1.02%
1M Leistung:
-8.88%
6M Leistung:
+26.08%
1J Leistung:
+0.45%
1-Tages-Spanne:
Value
$52.53
$54.18
1-Wochen-Bereich:
Value
$52.25
$54.45
52-Wochen-Spanne:
Value
$33.19
$62.98

Merus N V Stock (MRUS) Company Profile

Name
Firmenname
Merus N V
Name
Telefon
31 030 253 8800
Name
Adresse
YALELAAN 62, 3584 CM UTRECHT
Name
Mitarbeiter
260
Name
Twitter
@MerusNV
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
MRUS's Discussions on Twitter

Vergleichen Sie MRUS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
MRUS
Merus N V
53.33 4.10B 35.93M -244.56M -157.31M -3.95
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Merus N V Stock (MRUS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-13 Eingeleitet Piper Sandler Overweight
2025-02-07 Eingeleitet Wells Fargo Overweight
2024-11-21 Eingeleitet Goldman Buy
2024-10-24 Eingeleitet UBS Buy
2024-03-28 Eingeleitet Truist Buy
2024-03-04 Bestätigt Needham Buy
2023-11-02 Eingeleitet Canaccord Genuity Buy
2023-08-21 Eingeleitet TD Cowen Outperform
2022-08-02 Eingeleitet Stifel Buy
2022-02-11 Eingeleitet BMO Capital Markets Outperform
2022-02-10 Eingeleitet Needham Buy
2021-11-17 Fortgesetzt Guggenheim Buy
2021-06-07 Hochstufung Citigroup Neutral → Buy
2021-04-08 Eingeleitet William Blair Outperform
2021-03-16 Eingeleitet SVB Leerink Outperform
2020-06-26 Eingeleitet H.C. Wainwright Buy
2020-05-27 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2019-11-20 Fortgesetzt Guggenheim Buy
2019-06-28 Eingeleitet ROTH Capital Buy
2019-04-12 Fortgesetzt Guggenheim Buy
2019-04-03 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2019-03-27 Eingeleitet Berenberg Buy
2018-01-02 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2017-09-15 Eingeleitet RBC Capital Mkts Outperform
2017-03-21 Herabstufung Citigroup Buy → Neutral
2016-12-22 Hochstufung Citigroup Neutral → Buy
2016-11-07 Herabstufung Citigroup Buy → Neutral
2016-06-13 Eingeleitet Citigroup Buy
2016-06-13 Eingeleitet Guggenheim Buy
2016-06-13 Eingeleitet Wedbush Outperform
Alle ansehen

Merus N V Aktie (MRUS) Neueste Nachrichten

pulisher
Jun 18, 2025

Merus gains after mid-stage trial data for lead asset in head and neck cancer - MSN

Jun 18, 2025
pulisher
Jun 15, 2025

(MRUS) Technical Data - news.stocktradersdaily.com

Jun 15, 2025
pulisher
Jun 13, 2025

Merus N.V.’s SWOT analysis: promising antibody platform drives stock potential By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Merus N.V.’s SWOT analysis: promising antibody platform drives stock potential - Investing.com Nigeria

Jun 13, 2025
pulisher
Jun 11, 2025

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus (NASDAQ:BCAX) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 10, 2025

The Netherlands: Merus raises US$300m from underwritten public offering - Investors in Healthcare

Jun 10, 2025
pulisher
Jun 08, 2025

Why Merus N.V. (MRUS) Crashed On Wednesday - MSN

Jun 08, 2025
pulisher
Jun 05, 2025

Merus N.V. announces proposed public offering of common shares - MSN

Jun 05, 2025
pulisher
Jun 05, 2025

Merus dips 7%, prices $300M stock at $57 per share - MSN

Jun 05, 2025
pulisher
Jun 05, 2025

Merus Announces Public Offering of Common Shares - TipRanks

Jun 05, 2025
pulisher
Jun 04, 2025

Merus Raises $300m After ASCO Success - insights.citeline.com

Jun 04, 2025
pulisher
Jun 04, 2025

Sector Update: Health Care Stocks Mixed Premarket Wednesday - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

MRUS: Joint Managers Lead Successful Offering | MRUS Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Merus Prices $300 Million Stock Offering - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Merus N.V. (MRUS) Launches $300M Public Offering - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Merus N.V. announces public offering of common shares By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Merus Prices 5.26 Mln Shares At $57/Shr In Public Offering; To Raise Around $300 Mln - Nasdaq

Jun 04, 2025
pulisher
Jun 04, 2025

Merus N.V. Announces Pricing of Public Offering of Common Shares - The Manila Times

Jun 04, 2025
pulisher
Jun 03, 2025

Merus N.V. Announces Proposed Public Offering of Common Shares | - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Merus (MRUS) Initiates Public Offering to Fund Development | MRU - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Merus (MRUS) Initiates Public Offering to Fund Development | MRUS Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Merus N.V. announces public offering of common shares - Investing.com Australia

Jun 03, 2025
pulisher
Jun 03, 2025

Merus Plans Public Share Offering - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Drugmaker Merus slips after share offering launch - TradingView

Jun 03, 2025
pulisher
Jun 03, 2025

Merus N.V. Announces Proposed Public Offering of Common Shares - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

How to Take Advantage of moves in (MRUS) - news.stocktradersdaily.com

Jun 03, 2025
pulisher
Jun 01, 2025

e.l.f Beauty, Box And Joby Aviation Are Among Top 11 Mid-Cap Gainers Last Week (May 26-May 30): Are Others In Your Portfolio? - Benzinga

Jun 01, 2025
pulisher
May 29, 2025

Merus, N.V. Provides Updates on Clinical Development - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Merus NV Stock Skyrockets 8%: Bull Run Intact or Peak Approaching? - Daily Chhattisgarh News

May 29, 2025
pulisher
May 29, 2025

Merus Announces Promising Phase 2 Trial Results - TipRanks

May 29, 2025
pulisher
May 29, 2025

ASCO25: Merus wins in head-to-head with Bicara for head and neck cancer - Yahoo Finance

May 29, 2025
pulisher
May 27, 2025

Merus to Present at Upcoming Investor Conferences - GlobeNewswire

May 27, 2025
pulisher
May 27, 2025

Merus Showcases Next-Gen Cancer Antibody Platform at Two Premier Healthcare Conferences - Stock Titan

May 27, 2025
pulisher
May 27, 2025

Merus stock holds $85 target, Buy rating at H.C. Wainwright - Investing.com

May 27, 2025
pulisher
May 27, 2025

Merus stock holds $85 target, Buy rating at H.C. Wainwright By Investing.com - Investing.com India

May 27, 2025
pulisher
May 27, 2025

Merus (MRUS) Stock: Analysts Rally Behind Biotech After Cancer Treatment Breakthrough - CoinCentral

May 27, 2025
pulisher
May 27, 2025

Merus (NASDAQ:MRUS) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

May 27, 2025
pulisher
May 26, 2025

Merus (NASDAQ:MRUS) Given a $110.00 Price Target by BMO Capital Markets Analysts - Defense World

May 26, 2025
pulisher
May 26, 2025

Lazard Asset Management LLC Takes Position in Merus (NASDAQ:MRUS) - Defense World

May 26, 2025
pulisher
May 26, 2025

Merus (NASDAQ:MRUS) Price Target Raised to $110.00 - Defense World

May 26, 2025
pulisher
May 25, 2025

BofA Maintains Buy Rating on Merus (MRUS), Lifts PT - Yahoo Finance

May 25, 2025
pulisher
May 25, 2025

Merus N.V.’s SWOT analysis: promising cancer drug pipeline boosts stock outlook - Investing.com Australia

May 25, 2025
pulisher
May 25, 2025

Merus (MRUS) Price Target Raised at BMO After Positive Phase 2 Data - MSN

May 25, 2025

Finanzdaten der Merus N V-Aktie (MRUS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Merus N V-Aktie (MRUS) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Silverman Peter B.
COO & GC
Jun 20 '25
Sale
52.76
34,000
1,793,840
0
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):